Abstract PD07-03: INCREASED PATHOLOGIC COMPLETE RESPONSE RATE AFTER A LONG TERM NEOADJUVANT LETROZOLE TREATMENT IN POSTMENOPAUSAL ESTROGEN AND/OR PROGESTERONE RECEPTOR-POSITIVE BREAST CANCER

2012 ◽  
Author(s):  
G Allevi ◽  
C Strina ◽  
D Andreis ◽  
V Zanoni ◽  
L Bazzola ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Response Rate ◽  
Complete Response Rate ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Letrozole Treatment ◽  
Postmenopausal Estrogen ◽  
Pathologic Complete Response Rate ◽  
Positive Breast Cancer

scholarly journals Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Oncotarget ◽  
2018 ◽  
Vol 9 (41) ◽  
pp. 26406-26416 ◽  
Author(s):  
Angela Santonja ◽  
Alfonso Sánchez-Muñoz ◽  
Ana Lluch ◽  
Maria Rosario Chica-Parrado ◽  
Joan Albanell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Response Rate ◽  
Complete Response Rate ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Cancer Subtypes ◽  
Pathologic Complete Response Rate

scholarly journals Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer

2016 ◽  
Vol 11 (4) ◽  
pp. 863
Author(s):  
Quan Liang ◽  
Qiang Fu ◽  
Wei Li ◽  
Jiacong You ◽  
Zhanchao Zhao
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Response Rate ◽  
Complete Response Rate ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Cochrane Library ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

<p>The aim of this study was to compare the efficacy and safety of trastuzumab versus the combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy for HER2 positive breast cancer. PubMed, MEDLINE, The Cochrane Library, Web of Science and nearly 5 years of the important international conference on oncology records were searched for randomized clinical trials that compared lapatinib plus trastuzumab and neoadjuvant chemotherapy (NAC) with trastuzumab in combination with NAC and that included pathologic complete response rate as the primary outcome. Finally, 6 clinical randomized controlled trials were included. Meta-analysis shows that pathological complete response rate was significantly increased in trastu-zumab plus lapatinib group than single use trastuzumab group (53.4%, 40.4%, RR = 1.75, 95% CI 1.38 ~ 2.23, p&lt;0.001). In conclusion, the combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy in HER2 positive breast cancer is more effective.</p><p> </p>

Sign in / Sign up

Export Citation Format

Share Document